Ipsen Weighs U.S. Manufacturing Investment

Ipsen is weighing a U.S. production site, the latest European drugmaker to consider shifting new manufacturing investment across the Atlantic. The trend signals that pharma supply chains and capital spending are being reshaped by U.S. market and policy incentives, with implications for European industrial capacity and drug supply resilience.

• French drugmaker Ipsen is considering building a production facility in the U.S.
• The move follows other European companies eyeing the U.S. for new investments.
• Signals a broader reallocation of pharma manufacturing capital toward the U.S.